Life Science Partners
Consortium invest £16.9m in Atlas Genetics
A consortium, led by Novartis Venture and Consort Medical, has invested £16.9m in diagnostic company Atlas Genetics Ltd.
LSP et al. invest €8.1m in Mendor
A consortium, consisting of Life Sciences Partners (LSP), Finnish entrepreneur Risto Siilasmaa, Finnish Industry Investment, Ilmarinen Mutual Pension Insurance Company, Biothom and Finnvera Venture Capital, has participated in a €8.1m series-B funding...
Life Sciences Partners launches €250m fund
Life Sciences Partners has launched LSP Life Sciences Fund N.V. with a target of €250m.
Ysios et al. invest €18m in Cellerix
Existing investors have invested a further €18m in Spanish biopharma Cellerix, prior to its merger with Belgium-based TiGenix.
Lundbeckfond Ventures et al. invest €11.4m in Nexstim
A consortium of investors led by Lundbeckfond Ventures has invested €11.4m in Finnish medical equipment company Nexstim.
Syntaxin receives £18m investment
Lundbeckfond Ventures, Seventure and Ipsen have taken part in a series-C round of financing for biopharmaceutical company Syntaxin.
Consortium set to list Zealand Pharma
A consortium, consisting of Life Sciences Partners and Sunstone Capital among others, has announced its intention to list Zealand Pharma A/S on the NASDAQ OMX Copenhagen.
Strong research bodes bright future for Dutch venture
The Netherlands’ excellence in the fields of ICT and Life Sciences is driving dealflow up and prompting optimism for the future. By Francinia Protti-Alvarez
LSP in €21.7m series B round for Merus
Life Sciences Partners (LSP), Novartis Option Fund, Pfizer and Bay City Capital have co-led a €21.7m series B financing round for biopharmaceutical Merus.